Dr. Yongwei Hu | Nanotechnology | Best Researcher Award
Third Affiliated Hospital of Sun Yat-sen University, China
👨🎓Profiles
🎓 Early Academic Pursuits
Dr. Yongwei Hu embarked on his academic journey with a strong interest in biomedical sciences and nanotechnology. From the outset, his focus gravitated toward applying advanced materials to address critical challenges in cancer therapy. His education laid a solid foundation in molecular biology, materials science, and therapeutic design, equipping him with the tools needed for interdisciplinary innovation. This early dedication led him to the prestigious Third Affiliated Hospital of Sun Yat-sen University, where he now serves as an assistant research fellow.
💼 Professional Endeavors
Currently an Assistant Research Fellow at the Third Affiliated Hospital of Sun Yat-sen University, Dr. Hu has established himself at the forefront of cancer nanomedicine research. He is actively involved in developing innovative treatment strategies for hepatocellular carcinoma (HCC), leveraging his expertise in immunotherapy and nanotechnology. His work bridges clinical medicine and biomedical engineering, ensuring translational potential from lab to patient care.
🔬 Contributions and Research Focus
Dr. Hu’s research centers on designing multifunctional nanomaterials that integrate photothermal, chemotherapeutic, and immunotherapeutic capabilities. His key contributions include:
-
Co+diABZI@J-dICG nanoparticles, which synergize photothermal therapy with metalloimmunotherapy to activate anti-tumor immunity.
-
Co+Len@OVA nanoclusters, a pH-responsive system used in combination with anti-PD1 therapy to normalize tumor vasculature and boost immune infiltration.
-
An in-situ therapy platform using electrospun fibers, targeting post-surgical HCC recurrence with localized drug delivery and immune activation.
These innovations mark significant progress in precision oncology, where treatments are tailored for maximal efficacy and minimal systemic toxicity.
🌍 Impact and Influence
Dr. Hu’s pioneering research has significantly influenced the field of nano-enabled immunotherapy for liver cancer. By demonstrating new approaches to tumor eradication and recurrence prevention, his studies offer hope for long-term patient survival. His work has gained attention from peers in translational medicine and biomedical engineering, reinforcing his reputation as a rising leader in the integration of advanced materials with therapeutic innovation.
📈 Academic Citations and Recognition
Although early in his career, Dr. Hu’s impactful research has been recognized in academic communities through citations in high-quality journals and conference proceedings. His publications have laid foundational understanding for the therapeutic application of nanozymes, metalloimmunotherapy, and biomimetic delivery systems in hepatocellular carcinoma.
🛠️ Technical Skills
Dr. Hu is proficient in a variety of experimental techniques, including:
-
Photothermal and drug release assays (in vitro and in vivo)
-
Electrospinning technology for scaffold fabrication
-
Tumor immunology assays, including flow cytometry and immunohistochemistry
-
Murine model handling and tumor microenvironment analysis
👨🏫 Teaching Experience
Dr. Hu has contributed to mentoring graduate students and junior researchers in the field of nanomedicine. He guides experimental design, data analysis, and manuscript preparation, fostering a new generation of interdisciplinary scientists passionate about cancer therapy innovations.
🧬 Legacy and Future Contributions
Dr. Yongwei Hu aims to continue pushing the boundaries of nanomedicine by exploring next-generation biomaterials and personalized therapeutic systems. His future research will delve deeper into tumor immune microenvironment modulation, multimodal imaging-guided therapy, and long-acting therapeutic implants for cancer recurrence prevention. His legacy is shaping up to be one of impactful innovation at the interface of materials science and oncology.
📖Notable Publications
-
Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells
Authors: Siqi Li, Kun Li, Kang Wang, Haoyuan Yu, Xiangyang Wang, Mengchen Shi, Zhixing Liang, Zhou Yang, Yongwei Hu, Yang Li et al.
Journal: Nature Communications
Year: 2023 -
Self-intensified synergy of a versatile biomimetic nanozyme and doxorubicin on electrospun fibers to inhibit postsurgical tumor recurrence and metastasis
Authors: Yongwei Hu, Yanteng Xu, Rachel L. Mintz, Xing Luo, Youqiang Fang, Yeh-Hsing Lao, Hon Fai Chan, Kai Li, Shixian Lv, Guojun Chen et al.
Journal: Biomaterials
Year: 2023 -
Recent advances in nanomaterials for prostate cancer detection and diagnosis
Authors: Yongwei Hu, Shixian Lv, Jiaming Wan, Chunxiong Zheng, Dan Shao, Haixia Wang, Yu Tao, Mingqiang Li, Yun Luo
Journal: Journal of Materials Chemistry B
Year: 2022